Scientists Find Blood Test Predicting Dementia 10 Years Early

Scientists reported that a blood-based biomarker may help identify dementia-related risk well before symptoms appear, based on measurements of the protein p-tau217 in blood plasma among older adults who were asymptomatic at the time of testing.

The researchers found that higher concentrations of p-tau217 were associated with a markedly increased likelihood of later cognitive impairment. The data pointed to a 38% risk of impairment within five years for individuals with elevated levels, rising to 78% over a 10-year period.

p-tau217 results and the reported risk timeline

The central finding was a correlation between elevated p-tau217 in blood plasma and subsequent cognitive impairment in older adults who did not yet show symptoms. Officials involved in the research said the risk projections extended across two time horizons, with a five-year estimate and a longer 10-year estimate.

In the reported dataset, the five-year risk of impairment reached 38% for those with high p-tau217, and the 10-year risk rose to 78%. The researchers presented these figures as evidence that a blood test could offer long-range risk stratification in a population that may otherwise appear clinically normal.

How the biomarker compares with existing tools

According to the findings, the predictive signal from p-tau217 operated independently of common diagnostic measures. The researchers said this remained true even when considering amyloid PET imaging, which is often used to detect amyloid pathology, and genetic factors such as the APOE4 variant.

They argued that p-tau217 may reflect biological disease activity not fully captured by standard screening approaches. The study’s framing suggests the biomarker could add a distinct layer of information rather than duplicating what clinicians already infer from imaging or genetics.

Why routine screening is not being advised

Despite the reported association and the long forecast window, the blood test was not recommended for routine clinical screening of asymptomatic populations. Researchers pointed to a key limitation: there are no proven disease-modifying therapies specifically established for early-stage, symptom-free patients that would clearly change outcomes based on an earlier risk signal.

In practical terms, this means a result indicating elevated risk may not translate into an established, standard intervention for people who feel well and have no clinical impairment. The research therefore positioned the test as promising but not yet ready for broad, population-level use in general practice.

Potential near-term uses and open scientific questions

The researchers said future applications are more likely to center on identifying candidates for clinical trials and enabling more personalized risk assessments. In that context, a blood test could help select participants who are more likely to progress, supporting studies that aim to evaluate preventive or early-intervention strategies.

They also highlighted uncertainties that require additional research to refine long-term projections. Specifically, the team said factors such as renal function and cardiovascular comorbidities need to be accounted for, indicating that health conditions affecting physiology could influence biomarker levels or how reliably they track future impairment.

For now, the study adds to ongoing efforts to move dementia research toward earlier detection using less invasive tools, while underscoring that clinical adoption depends not only on prediction accuracy but also on the availability of proven actions for symptom-free individuals.